| Year |
Citation |
Score |
| 2023 |
Shah VM, Rizvi S, Smith A, Tsuda M, Krieger M, Pelz C, MacPherson K, Eng J, Chin K, Munks MW, Daniel CJ, Al-Fatease A, Yardimci GG, Langer EM, Brody JR, et al. Micelle-Formulated Juglone Effectively Targets Pancreatic Cancer and Remodels the Tumor Microenvironment. Pharmaceutics. 15. PMID 38139993 DOI: 10.3390/pharmaceutics15122651 |
0.366 |
|
| 2023 |
Finan JM, Sutton TL, Dixon DA, Brody JR. Targeting the RNA-binding protein HuR in cancer. Cancer Research. PMID 37683260 DOI: 10.1158/0008-5472.CAN-23-0972 |
0.367 |
|
| 2023 |
McCarthy GA, Di Niro R, Finan JM, Jain A, Guo Y, Wyatt CR, Guimaraes AR, Waugh TA, Keith D, Morgan TK, Sears RC, Brody JR. Deletion of the mRNA stability factor (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity. Nar Cancer. 5: zcad016. PMID 37089813 DOI: 10.1093/narcan/zcad016 |
0.302 |
|
| 2022 |
Korzun T, Moses AS, Kim J, Patel S, Schumann C, Levasseur PR, Diba P, Olson B, Rebola KGO, Norgard M, Park Y, Demessie AA, Eygeris Y, Grigoriev V, Sundaram S, ... ... Brody JR, et al. Nanoparticle-Based Follistatin Messenger RNA Therapy for Reprogramming Metastatic Ovarian Cancer and Ameliorating Cancer-Associated Cachexia. Small (Weinheim An Der Bergstrasse, Germany). e2204436. PMID 36098251 DOI: 10.1002/smll.202204436 |
0.321 |
|
| 2022 |
Vaziri-Gohar A, Cassel J, Mohammed FS, Zarei M, Hue JJ, Hajihassani O, Graor HJ, Srikanth YVV, Karim SA, Abbas A, Prendergast E, Chen V, Katayama ES, Dukleska K, Khokhar I, ... ... Brody JR, et al. Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors. Nature Cancer. PMID 35681100 DOI: 10.1038/s43018-022-00393-y |
0.339 |
|
| 2021 |
Shupp AB, Neupane M, Agostini LC, Ning G, Brody JR, Bussard KM. Stromal-derived extracellular vesicles suppress proliferation of bone metastatic cancer cells mediated by ERK2. Molecular Cancer Research : McR. PMID 34021072 DOI: 10.1158/1541-7786.MCR-20-0981 |
0.309 |
|
| 2020 |
Pishvaian MJ, Wang H, He AR, Hwang JJ, Smaglo BG, Kim SS, Weinberg BA, Weiner LM, Marshall JL, Brody JR. A Phase I/II Study of Veliparib (ABT-888) in combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32669374 DOI: 10.1158/1078-0432.Ccr-20-1301 |
0.317 |
|
| 2020 |
Lowder CY, Dhir T, Goetz AB, Thomsett HL, Bender J, Tatarian T, Madhavan S, Petricoin EF, Blais E, Lavu H, Winter JM, Posey J, Brody JR, Pishvaian MJ, Yeo CJ. A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience. Surgical Oncology. 33: 118-125. PMID 32561076 DOI: 10.1016/J.Suronc.2020.02.003 |
0.384 |
|
| 2020 |
Pishvaian MJ, Blais EM, Brody JR, Lyons E, DeArbeloa P, Hendifar A, Mikhail S, Chung V, Sahai V, Sohal DPS, Bellakbira S, Thach D, Rahib L, Madhavan S, Matrisian LM, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. The Lancet. Oncology. PMID 32135080 DOI: 10.1016/S1470-2045(20)30074-7 |
0.414 |
|
| 2020 |
Nevler A, Brown SZ, Nauheim D, Portocarrero C, Bassig J, Schultz CW, McCarthy G, Lavu H, Yeo TP, Yeo CJ, Brody JR. Effect of Hypercapnia, an Element of Obstructive Respiratory Disorders, on Pancreatic Cancer Chemoresistance and Progression. Journal of the American College of Surgeons. PMID 32058016 DOI: 10.1016/J.Jamcollsurg.2019.12.033 |
0.352 |
|
| 2020 |
Schultz CW, Preet R, Dhir T, Dixon DA, Brody JR. Understanding and targeting the disease-related RNA binding protein human antigen R (HuR). Wiley Interdisciplinary Reviews. Rna. e1581. PMID 31970930 DOI: 10.1002/Wrna.1581 |
0.43 |
|
| 2020 |
Hendifar AE, Blais EM, Ng C, Thach D, Gong J, Sohal D, Chung V, Sahai V, Fountzilas C, Mikhail S, Gregory G, Brody JR, Lyons E, DeArbeloa P, Matrisian LM, et al. Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC): Clinical/molecular correlations and real-world outcomes across standard therapies. Journal of Clinical Oncology. 38: 4641-4641. DOI: 10.1200/Jco.2020.38.15_Suppl.4641 |
0.38 |
|
| 2020 |
Brown SZ, Schultz CW, Nevler A, Li T, Jain A, O’Neil R, Jiang W, Londin E, Dixon DA, Xu L, Yeo CJ, Brody JR. Abstract B45: A feedback gene regulatory mechanism between YAP1 and the RNA-binding protein, Human Antigen R (HuR), in pancreatic cancer cells: Implications for a context-dependent pancreatic cancer cell survival network Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Hippo19-B45 |
0.476 |
|
| 2020 |
McCarthy GA, Jain A, Brown SZ, Yeo CJ, Brody J. Abstract LB-203: The mRNA binding protein Human Antigen R (HuR, ELAVL1) is a novel regulator in pancreatic ductal adenocarcinoma metastatic progression and persistence Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Lb-203 |
0.446 |
|
| 2019 |
Armstrong SA, Schultz CW, Azimi-Sadjadi A, Brody JR, Pishvaian MJ. ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications. Molecular Cancer Therapeutics. 18: 1899-1908. PMID 31676541 DOI: 10.1158/1535-7163.Mct-19-0208 |
0.373 |
|
| 2019 |
Dhir T, Schultz CW, Jain A, Brown SZ, Haber A, Goetz A, Xi C, Su GH, Xu L, Posey J, Jiang W, Yeo CJ, Golan T, Pishvaian MJ, Brody JR. Abemaciclib is effective against pancreatic cancer cells and synergizes with HuR and YAP1 inhibition. Molecular Cancer Research : McR. PMID 31383722 DOI: 10.1158/1541-7786.Mcr-19-0589 |
0.419 |
|
| 2019 |
Brar G, Blais EM, Joseph Bender R, Brody JR, Sohal D, Madhavan S, Picozzi VJ, Hendifar AE, Chung VM, Halverson D, Mikhail S, Matrisian LM, Rahib L, Petricoin E, Pishvaian MJ. Multi-omic molecular comparison of primary versus metastatic pancreatic tumours. British Journal of Cancer. PMID 31292535 DOI: 10.1038/S41416-019-0507-5 |
0.366 |
|
| 2019 |
Jain A, Agostini LC, McCarthy GA, Chand SN, Ramirez A, Nevler A, Cozzitorto J, Schultz CW, Lowder CY, Smith KM, Waddell ID, Raitses-Gurevich M, Stossel C, Gorman YG, Atias D, ... ... Brody JR, et al. Poly (ADP) ribose glycohydrolase can be effectively targeted in pancreatic cancer. Cancer Research. PMID 31273064 DOI: 10.1158/0008-5472.Can-18-3645 |
0.41 |
|
| 2019 |
Parasido E, Avetian G, Naeem A, Graham G, Pishvaian M, Glasgow E, Mudambi S, Lee Y, Ihemelandu C, Choudhry M, Peran I, Banerjee PP, Avantaggiati ML, Bryant K, Baldelli E, ... ... Brody JR, et al. The sustained induction of c-Myc drives nab-paclitaxel resistance in primary pancreatic ductal carcinoma cells. Molecular Cancer Research : McR. PMID 31164413 DOI: 10.1158/1541-7786.Mcr-19-0191 |
0.336 |
|
| 2019 |
Jain A, Brown SZ, Thomsett HL, Londin E, Brody JR. Evaluation of Post-transcriptional Gene Regulation in Pancreatic Cancer Cells: Studying RNA Binding Proteins and Their mRNA Targets. Methods in Molecular Biology (Clifton, N.J.). 1882: 239-252. PMID 30378060 DOI: 10.1007/978-1-4939-8879-2_22 |
0.389 |
|
| 2019 |
Pishvaian MJ, Blais EM, Brody JR, Sohal D, Hendifar AE, Chung V, Mikhail S, Rahib L, Lyons E, Tibbetts L, Madhavan S, Matrisian LM, Petricoin E. Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: Results from the Know Your Tumor (KYT) program. Journal of Clinical Oncology. 37: 191-191. DOI: 10.1200/Jco.2019.37.4_Suppl.191 |
0.302 |
|
| 2019 |
Pishvaian MJ, Blais EM, DeArbeloa P, Brody JR, Rahib L, Hendifar AE, Mikhail S, Chung V, Sohal D, Picozzi VJ, Mason K, Tibbetts L, Lyons E, Matrisian LM, Madhavan S, et al. Improved overall survival (OS) for advanced pancreatic cancer (PDAC) patients (pts) enrolled in the Know Your Tumor (KYT) program whose tumors harbored highly actionable molecular alterations and who received molecularly-matched therapies (tx). Journal of Clinical Oncology. 37: 4138-4138. DOI: 10.1200/Jco.2019.37.15_Suppl.4138 |
0.34 |
|
| 2019 |
Prendergast GC, Nevler A, Muller AJ, Sutanto-Ward E, DuHadaway JB, Nagatomo K, Londin E, O'Hayer K, Cozzitorto JA, Lavu H, Yeo TP, Curtis M, Villatoro T, Leiby BE, Winter JM, ... ... Brody JR, et al. Abstract A101: IDO2 host genetic status influences progression and radiotherapy response in pancreatic ductal adenocarcinoma Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A101 |
0.408 |
|
| 2019 |
Vaziri-Gohar A, Khokhar I, Titomihelakis G, Brody JR, Winter JM. Abstract LB-117: Increased peripheral glucose levels restores chemotherapeutic efficacy in a mouse model of pancreatic cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-117 |
0.42 |
|
| 2019 |
Jain A, McCoy M, Agostini LA, Gusev Y, Madhavan S, Pishvaian M, Addya S, Londin E, Gurevich MR, Stossel C, Golan T, Yeo CJ, Brody JR. Abstract 4764: A global transcriptome analysis of pancreatic cancer cells distinguishes between acute and acquired PARP inhibitor resistance mechanisms Cancer Research. 79: 4764-4764. DOI: 10.1158/1538-7445.Am2019-4764 |
0.43 |
|
| 2019 |
Brown SZ, Schultz CW, Li T, Jain A, O'Neill R, Jiang W, Yeo CP, Brody JR. Abstract 4388: A novel, reversible YAP1-HuR axis promotes pancreatic tumorigenesis Cancer Research. 79: 4388-4388. DOI: 10.1158/1538-7445.Am2019-4388 |
0.445 |
|
| 2019 |
McCarthy G, Schultz C, Jain A, Dhir T, Yeo C, Bowers J, Casta L, Rhodes K, Getts L, Getts R, Baybutt T, Snook A, Brody J. Abstract 3614: Targeted 3DNA-siHuR nanocarrier therapy for pancreatic ductal adenocarcinoma Cancer Research. 79: 3614-3614. DOI: 10.1158/1538-7445.Am2019-3614 |
0.394 |
|
| 2019 |
Parasido EM, Avetian GS, Brody J, Winter J, Londin E, Pishvaian M, Glasgow E, Byers S, Narla G, Albanese C. Abstract 1283: Targeting c-MYC and MAPK pathway to overcome pancreatic cancer drug resistance Cancer Research. 79: 1283-1283. DOI: 10.1158/1538-7445.Am2019-1283 |
0.359 |
|
| 2019 |
Matrisian LM, Blais EM, Lyons E, Moravek C, Dearbeloa P, Madhavan S, Brody JR, Petricoin E, Pishvaian MJ. Precision Oncology for Pancreatic Cancer across the United States: the Know Your Tumor ® experience Annals of Oncology. 30: vi30. DOI: 10.1093/Annonc/Mdz348.001 |
0.417 |
|
| 2019 |
Dhir T, Schultz C, Jain A, Yeo CJ, Golan T, Brody JR. 926 – Abemaciclib is Effective Against Pancreatic Cancer Cells and Synergizes with Hur and Yap1 Inhibition Gastroenterology. 156. DOI: 10.1016/S0016-5085(19)40592-1 |
0.438 |
|
| 2018 |
Vaziri-Gohar A, Zarei M, Brody JR, Winter JM. Corrigendum: Metabolic Dependencies in Pancreatic Cancer. Frontiers in Oncology. 8: 672. PMID 30805300 DOI: 10.3389/Fonc.2018.00672 |
0.349 |
|
| 2018 |
Vaziri-Gohar A, Zarei M, Brody JR, Winter JM. Metabolic Dependencies in Pancreatic Cancer. Frontiers in Oncology. 8: 617. PMID 30631752 DOI: 10.3389/Fonc.2018.00617 |
0.349 |
|
| 2018 |
Nevler A, Muller AJ, Sutanto-Ward E, DuHadaway JB, Nagatomo K, Londin E, O'Hayer K, Cozzitorto JA, Lavu H, Yeo TP, Curtis MT, Villatoro T, Leiby BE, Mandik-Nayak L, Winter JM, ... ... Brody JR, et al. Host gene status influences tumor progression and radiotherapy response in -driven sporadic pancreatic cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30266763 DOI: 10.1158/1078-0432.Ccr-18-0814 |
0.388 |
|
| 2018 |
Zarei M, Lal S, Vaziri-Gohar A, O'Hayer K, Gunda V, Singh PK, Brody JR, Winter JM. RNA-binding Protein HuR Regulates Both Mutant and Wild-type IDH1 in IDH1-mutated Cancer. Molecular Cancer Research : McR. PMID 30266754 DOI: 10.1158/1541-7786.Mcr-18-0557 |
0.4 |
|
| 2018 |
Pan H, Strickland A, Madhu V, Johnson ZI, Chand SN, Brody JR, Fertala A, Zheng Z, Shapiro IM, Risbud MV. RNA binding protein HuR regulates extracellular matrix gene expression and pH homeostasis independent of controlling HIF-1α signaling in nucleus pulposus cells. Matrix Biology : Journal of the International Society For Matrix Biology. PMID 30092282 DOI: 10.1016/J.Matbio.2018.08.003 |
0.331 |
|
| 2018 |
Pishvaian MJ, Bender RJ, Halverson D, Rahib L, Hendifar AE, Mikhail S, Chung V, Picozzi VJ, Sohal D, Blais EM, Mason K, Lyons EE, Matrisian LM, Brody JR, Madhavan S, et al. Molecular Profiling of Pancreatic Cancer Patients: Initial Results from the Know Your Tumor Initiative. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29954777 DOI: 10.1158/1078-0432.Ccr-18-0531 |
0.402 |
|
| 2018 |
Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville T, Froeling FEM, Burkhart RA, Denroche RE, Jang GH, Miyabayashi K, Young CM, Patel H, Ma M, LaComb JF, ... ... Brody JR, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discovery. PMID 29853643 DOI: 10.1158/2159-8290.Cd-18-0349 |
0.439 |
|
| 2018 |
Pishvaian MJ, Slack RS, Jiang W, He AR, Hwang JJ, Hankin A, Dorsch-Vogel K, Kukadiya D, Weiner LM, Marshall JL, Brody JR. A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer. Cancer. PMID 29579325 DOI: 10.1002/Cncr.31309 |
0.346 |
|
| 2018 |
Maranto C, Udhane V, Hoang DT, Gu L, Alexeev V, Malas KM, Cardenas K, Brody JR, Rodeck U, Bergom C, Iczkowski KA, Jacobsohn K, See WA, Schmitt SM, Nevalainen MT. STAT5A/B BLOCKADE SENSITIZES PROSTATE CANCER TO RADIATION THROUGH INHIBITION OF RAD51 AND DNA REPAIR. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29483142 DOI: 10.1158/1078-0432.Ccr-17-2768 |
0.34 |
|
| 2018 |
Brody JR, Dixon DA. Complex HuR function in pancreatic cancer cells. Wiley Interdisciplinary Reviews. Rna. PMID 29452455 DOI: 10.1002/Wrna.1469 |
0.443 |
|
| 2018 |
Nevler A, Muller AJ, Cozzitorto JA, Goetz A, Winter JM, Yeo TP, Lavu H, Yeo CJ, Prendergast GC, Brody JR. A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss of Function Polymorphisms and Indoleamine-2,3-Dioxygenase-2. Journal of the American College of Surgeons. PMID 29426021 DOI: 10.1016/J.Jamcollsurg.2017.12.052 |
0.362 |
|
| 2018 |
Petricoin E, Bender RJ, Halverson DC, Rahib L, Hendifar AE, Mikhail S, Chung VM, Picozzi VJ, Sohal D, Matrisian LM, Brody JR, Madhavan S, Pishvaian MJ. Precision medicine for pancreatic cancer patients:preliminary results from the know your tumor program. Journal of Clinical Oncology. 36: 4126-4126. DOI: 10.1200/Jco.2018.36.15_Suppl.4126 |
0.374 |
|
| 2018 |
Avetian GS, Parasido EM, Brody J, Winter J, Londin E, Pishvaian M, Glasgow E, Byers S, Albanese C. Abstract 4073: Using patient-derived PDAC cells to understand c-MYC involvement in the drug resistance mechanisms of pancreatic cancer Cancer Research. 78: 4073-4073. DOI: 10.1158/1538-7445.Am2018-4073 |
0.38 |
|
| 2018 |
Chand SN, Ramirez A, Jain A, Nevler A, Yabar-Lowder C, Cozzitorto JA, James DI, Jordan AM, Smith KM, Waddell ID, Yeo CJ, Winter JM, Brody JR. Abstract 1973: Targeting PARG in pancreatic cancer: Implications for synthetic lethal therapeutic strategies Cancer Research. 78: 1973-1973. DOI: 10.1158/1538-7445.Am2018-1973 |
0.43 |
|
| 2018 |
Schultz CW, O'Hayer K, Dhir T, Bolaji O, Bormes KM, Brown SZ, Thomsett H, Chand S, Jain A, Jiang W, McCarthy G, Yeo CJ, Goetz A, Nevler A, Brody JR, et al. Abstract 1961: Gaps in the armor: Targeting HuR to sensitize pancreatic cancer Cancer Research. 78: 1961-1961. DOI: 10.1158/1538-7445.Am2018-1961 |
0.46 |
|
| 2018 |
Schultz CW, O'Hayer K, Bormes KM, Dhir T, Brown S, Nevlar A, Chand S, Thomsett H, Jiang W, Bowers J, Rhodes K, Pishvaian M, Getts R, Brody J. Abstract LB-B19: Re-sensitizing Pancreatic Cancer, targeted siRNA inhibition of HuR Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Lb-B19 |
0.472 |
|
| 2018 |
Vaziri-Gohar A, Dukleska K, Brody JR, Winter JM. Abstract LB-B05: Targeting IDH1 inhibits survival and growth of pancreatic cancer cells Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Lb-B05 |
0.45 |
|
| 2018 |
Chand SN, Ramirez A, Jain A, Nevlar A, Yabar-Lowder C, Cozzitorto JA, James DI, Waddell ID, Yeo CJ, Pishvaian MJ, Winter JM, Brody JR. Abstract LB-A13: Targeting poly-ADP ribose glycohydrolase: pursuing a synthetic lethal therapeutic strategy to treat all pancreatic cancers Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Lb-A13 |
0.457 |
|
| 2017 |
Pishvaian MJ, Joseph Bender R, Matrisian LM, Rahib L, Hendifar A, Hoos WA, Mikhail S, Chung V, Picozzi V, Heartwell C, Mason K, Varieur K, Aberra M, Madhavan S, Petricoin E, ... Brody JR, et al. A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. Oncotarget. 8: 83446-83456. PMID 29137355 DOI: 10.18632/Oncotarget.13225 |
0.342 |
|
| 2017 |
Peng W, Furuuchi N, Aslanukova L, Huang YH, Brown SZ, Jiang W, Addya S, Vishwakarma V, Peters E, Brody JR, Dixon DA, Sawicki JA. Elevated HuR in Pancreas Promotes a Pancreatitis-like Inflammatory Microenvironment that Facilitates Tumor Development. Molecular and Cellular Biology. PMID 29133460 DOI: 10.1128/Mcb.00427-17 |
0.409 |
|
| 2017 |
Chand SN, Zarei M, Schiewer MJ, Kamath AR, Romeo C, Lal S, Cozzitorto JA, Nevler A, Scolaro L, Londin E, Jiang W, Meisner-Kober N, Pishvaian MJ, Knudsen KE, Yeo CJ, ... ... Brody JR, et al. Post-transcriptional regulation of PARG mRNA by HuR facilitates DNA repair and resistance to PARP inhibitors. Cancer Research. PMID 28687616 DOI: 10.1158/0008-5472.Can-16-2704 |
0.42 |
|
| 2017 |
Zarei M, Lal S, Parker SJ, Nevler A, Vaziri-Gohar A, Dukleska K, Mambelli-Lisboa NC, Moffat C, Blanco FF, Chand SN, Jimbo M, Cozzitorto JA, Jiang W, Yeo CJ, Londin E, ... ... Brody JR, et al. Posttranscriptional upregulation of IDH1 by HuR establishes a powerful survival phenotype in pancreatic cancer cells. Cancer Research. PMID 28652247 DOI: 10.1158/0008-5472.Can-17-0015 |
0.424 |
|
| 2017 |
Pishvaian MJ, Brody JR. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer. Oncology (Williston Park, N.Y.). 31. PMID 28299752 |
0.317 |
|
| 2017 |
Pishvaian MJ, Biankin AV, Bailey P, Chang DK, Laheru D, Wolfgang CL, Brody JR. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. British Journal of Cancer. PMID 28291774 DOI: 10.1038/Bjc.2017.40 |
0.424 |
|
| 2017 |
Lal S, Cheung EC, Zarei M, Preet R, Chand SN, Mambelli-Lisboa NC, Romeo C, Stout MC, Londin E, Goetz A, Lowder CY, Nevler A, Yeo CJ, Campbell PM, Winter JM, ... ... Brody JR, et al. CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype. Molecular Cancer Research : McR. PMID 28242812 DOI: 10.1158/1541-7786.Mcr-16-0361 |
0.48 |
|
| 2017 |
Jinawath N, Shiao MS, Norris A, Murphy K, Klein AP, Yonescu R, Iacobuzio-Donahue C, Meeker A, Jinawath A, Yeo CJ, Eshleman JR, Hruban RH, Brody JR, Griffin CA, Harada S. Alterations of type II classical cadherin Cadherin-10 (CDH10) is associated with pancreatic ductal adenocarcinomas. Genes, Chromosomes & Cancer. PMID 28124395 DOI: 10.1002/Gcc.22447 |
0.389 |
|
| 2017 |
Bender RJ, Halverson D, Mason K, Luo L, Brody JR, Rahib L, Matrisian LM, Hendifar AE, Hoos WA, Mikhail S, Chung VM, Picozzi VJ, Ramos C, Heartwell C, Varieur K, et al. Molecular biomarkers as predictors of patient survival in pancreatic adenocarcinoma (PDA): An analysis of the Know Your Tumor initiative (KYT). Journal of Clinical Oncology. 35: 278-278. DOI: 10.1200/Jco.2017.35.4_Suppl.278 |
0.364 |
|
| 2017 |
Parasido EM, Sripadhan P, Avetian G, Schlegel R, Brody J, Winter J, Yeo CJ, Pishvaian MJ, Glasgow E, Byers S, Albanese C. Abstract 812: Multiplatform modeling of pancreatic cancer using patient-derived cells: A new approach for defining drug resistance mechanisms Cancer Research. 77: 812-812. DOI: 10.1158/1538-7445.Am2017-812 |
0.375 |
|
| 2017 |
Vaziri-Gohar A, Zarei M, Brody JR, Winter JM. Abstract 100: Pancreatic cancer cells rely on the NADPH producing enzyme, IDH1, for adaptive survival against acute metabolic stress Cancer Research. 77: 100-100. DOI: 10.1158/1538-7445.Am2017-100 |
0.42 |
|
| 2016 |
Tatarian T, Jiang W, Leiby BE, Grigoli A, Jimbo M, Dabbish N, Neoptolemos JP, Greenhalf W, Costello E, Ghaneh P, Halloran C, Palmer D, Buchler M, Yeo CJ, Winter JM, ... Brody JR, et al. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial. Annals of Surgery. PMID 27893535 DOI: 10.1097/Sla.0000000000002088 |
0.386 |
|
| 2016 |
Rao S, Beckman RA, Riazi S, Yabar CS, Boca SM, Marshall JL, Pishvaian MJ, Brody JR, Madhavan S. Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment. Oncotarget. PMID 27888622 DOI: 10.18632/Oncotarget.13544 |
0.352 |
|
| 2016 |
Blanco FF, Preet R, Aguado A, Vishwakarma V, Stevens LE, Vyas A, Padhye S, Xu L, Weir SJ, Anant S, Meisner-Kober N, Brody JR, Dixon DA. Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis. Oncotarget. PMID 27677075 DOI: 10.18632/Oncotarget.12189 |
0.42 |
|
| 2016 |
Lal S, Zarei M, Chand SN, Dylgjeri E, Mambelli-Lisboa NC, Pishvaian MJ, Yeo CJ, Winter JM, Brody JR. WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner. Scientific Reports. 6: 33323. PMID 27616351 DOI: 10.1038/Srep33323 |
0.383 |
|
| 2016 |
Brody JR, Yabar CS, Zarei M, Bender J, Matrisian LM, Rahib L, Heartwell C, Mason K, Yeo CJ, Peiper SC, Jiang W, Varieur K, Madhavan S, Petricoin E, Fortuna D, et al. Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. Cancer Biology & Therapy. 0. PMID 27466707 DOI: 10.1080/15384047.2016.1210743 |
0.376 |
|
| 2016 |
Zhou H, Telonis AG, Jing Y, Xia NL, Biederman L, Jimbo M, Blanco F, Londin E, Brody JR, Rigoutsos I. GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR. Cell Death & Disease. 7: e2294. PMID 27415424 DOI: 10.1038/Cddis.2016.169 |
0.488 |
|
| 2016 |
Romeo C, Weber MC, Zarei M, DeCicco D, Chand SN, Lobo AD, Winter JM, Sawicki JA, Sachs JN, Meisner-Kober N, Yeo CJ, Vadigepalli R, Tykocinski ML, Brody JR. HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells. Molecular Cancer Research : McR. PMID 27053682 DOI: 10.1158/1541-7786.Mcr-15-0448 |
0.398 |
|
| 2016 |
O Hayer KM, Brody JR. Personalized therapy for pancreatic cancer: Do we need better targets, arrows, or both? Discovery Medicine. 21: 117-23. PMID 27011047 |
0.334 |
|
| 2016 |
Huang YH, Peng W, Furuuchi N, DuHadaway JB, Jimbo M, Pirritano A, Dunton CJ, Daum GS, Leiby BE, Brody JR, Sawicki JA. Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy. Oncotarget. PMID 26943573 DOI: 10.18632/Oncotarget.7840 |
0.456 |
|
| 2016 |
Chand S, O'Hayer K, Blanco FF, Winter JM, Brody JR. The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms. International Journal of Biological Sciences. 12: 273-82. PMID 26929734 DOI: 10.7150/Ijbs.14951 |
0.432 |
|
| 2016 |
Huang YH, Peng W, Furuuchi N, Gerhart JV, Rhodes K, Mukherjee N, Jimbo M, Gonye GE, Brody JR, Getts RC, Sawicki JA. Delivery of therapeutics targeting the mRNA-binding protein HuR using 3DNA nanocarriers suppresses ovarian tumor growth. Cancer Research. PMID 26921342 DOI: 10.1158/0008-5472.Can-15-2073 |
0.474 |
|
| 2016 |
Knudsen ES, O'Reilly EM, Brody JR, Witkiewicz AK. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology. 150: 48-63. PMID 26385075 DOI: 10.1053/J.Gastro.2015.08.056 |
0.344 |
|
| 2016 |
Pishvaian MJ, Brody JR, Matrisian L, Hendifar AE, Engebretson A, Hoos WA, Mikhail S, Chung VM, Picozzi VJ, Ramos C, Heartwell C, Mason K, Varieur K, Rahib L, Petricoin E, et al. Multi-Omic profiling (MoP) for patients (pts) with pancreatic cancer (PDA): Initial results of the Know Your Tumor (KYT) initiative. Journal of Clinical Oncology. 34: 282-282. DOI: 10.1200/Jco.2016.34.4_Suppl.282 |
0.388 |
|
| 2016 |
Engebretson A, Brody JR, Rahib L, Matrisian L, Hendifar AE, Hoos WA, Mikhail S, Chung VM, Picozzi VJ, Heartwell C, Mason K, Varieur K, Madhavan S, Petricoin E, Pishvaian MJ. The Know Your Tumor (KYT) initiative: A national program of multi-omic molecular profiling (MoP) for patients (Pts) with pancreatic cancer (PDA). Journal of Clinical Oncology. 34: 279-279. DOI: 10.1200/Jco.2016.34.4_Suppl.279 |
0.343 |
|
| 2016 |
Pishvaian MJ, Matrisian L, Hendifar AE, Engebretson A, Rahib L, Hoos WA, Mikhail S, Chung VM, Picozzi VJ, Heartwell C, Mason K, Varieur K, Madhavan S, Petricoin E, Brody JR. Preliminary observations of blood-based (BB) molecular testing in a subset of patients with pancreatic cancer (PDA) participating in the Know Your Tumor (KYT) initiative. Journal of Clinical Oncology. 34: 268-268. DOI: 10.1200/Jco.2016.34.4_Suppl.268 |
0.38 |
|
| 2016 |
Parasido EM, Sripadhan P, Schlegel R, Pishvaian MJ, Brody J, Winter J, Albanese C. Abstract B15: Patient-derived Pancreatic Adenocarcinoma cells: A new model system to define chemotherapy resistance mechanisms and to improve targeted personalized treatment Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-B15 |
0.371 |
|
| 2016 |
Zarei M, Blanco FF, Boros LG, Yeo CJ, Brody JR, Winter JM. Abstract B41: Post-transcriptional regulation of IDH1 by the RNA-binding protein HuR is important for pancreatic cancer cell survival under nutrient deprivation Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Metca15-B41 |
0.419 |
|
| 2016 |
Zhou H, Telonis A, Jing Y, Jimbo M, Blanco F, Londin E, Brody J, Rigoutsos I. Abstract A41: GPRC5A acts as a potent oncogene in pancreatic cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-A41 |
0.361 |
|
| 2016 |
Rahib L, Engebretson A, Pishvaian MJ, Brody JR, Hoos WA, Lyons EE, Bender J, Petricoin EF, Madhavan S, Heartwell C, Matrisian LM. Abstract 93: Molecular profiling of pancreatic cancer patients from a wide geographical distribution across the US Cancer Research. 76: 93-93. DOI: 10.1158/1538-7445.Am2016-93 |
0.373 |
|
| 2016 |
Cheung E, Lal S, Zarei M, Mambelli-Lisboa NC, Chand S, Romeo C, O’Hayer K, Londin E, Cozzitorto JA, Yeo CJ, Winter JM, Brody JR. Abstract 2854: CRISPR knockout of HuR in pancreatic cancer cells causes a xenograft lethal phenotype Cancer Research. 76: 2854-2854. DOI: 10.1158/1538-7445.Am2016-2854 |
0.459 |
|
| 2016 |
Chand SN, Zarei M, Kamath AR, Schiewer MJ, Romeo C, Cozzitorto JA, Meisner-Kober N, Londin E, Rigoutsos I, Knudsen K, Pascal JM, Yeo CJ, Winter JM, Brody JR. Abstract 1995: HuR dependent inhibition of PARG enhances PARP inhibitor therapy for DNA repair proficient and deficient pancreatic cancer cells Cancer Research. 76: 1995-1995. DOI: 10.1158/1538-7445.Am2016-1995 |
0.404 |
|
| 2016 |
Zarei M, Lal S, Mambelli-Lisboa NC, Cheung E, Chand SN, Yeo CJ, Brody JR, Winter JM. Abstract 1847: The mRNA-binding protein HuR, regulates mutant and wild type IDH1 expression in IDH1-mutated cancer Cancer Research. 76: 1847-1847. DOI: 10.1158/1538-7445.Am2016-1847 |
0.364 |
|
| 2015 |
Weinberg BA, Yabar CS, Brody JR, Pishvaian MJ. Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma. Oncology (Williston Park, N.Y.). 29: 809-20, 886. PMID 26573060 |
0.327 |
|
| 2015 |
Blanco FF, Jimbo M, Wulfkuhle J, Gallagher I, Deng J, Enyenihi L, Meisner-Kober N, Londin E, Rigoutsos I, Sawicki JA, Risbud MV, Witkiewicz AK, McCue PA, Jiang W, Rui H, ... ... Brody JR, et al. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells. Oncogene. PMID 26387536 DOI: 10.1038/Onc.2015.325 |
0.425 |
|
| 2015 |
Jimbo M, Blanco FF, Huang YH, Telonis AG, Screnci BA, Cosma GL, Alexeev V, Gonye GE, Yeo CJ, Sawicki JA, Winter JM, Brody JR. Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells. Oncotarget. PMID 26314962 DOI: 10.18632/Oncotarget.4743 |
0.447 |
|
| 2015 |
Witkiewicz AK, Borja NA, Franco J, Brody JR, Yeo CJ, Mansour J, Choti MA, McCue P, Knudsen ES. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. Oncotarget. 6: 15788-801. PMID 26158861 DOI: 10.18632/Oncotarget.3819 |
0.413 |
|
| 2015 |
Kozak G, Blanco FF, Brody JR. Novel targets in pancreatic cancer research. Seminars in Oncology. 42: 177-87. PMID 25726061 DOI: 10.1053/J.Seminoncol.2014.12.015 |
0.428 |
|
| 2015 |
Cozzitorto JA, Jimbo M, Chand S, Blanco F, Lal S, Gilbert M, Winter JM, Gorospe M, Brody JR. Studying RNA-binding protein interactions with target mRNAs in eukaryotic cells: native ribonucleoprotein immunoprecipitation (RIP) assays. Methods in Molecular Biology (Clifton, N.J.). 1262: 239-46. PMID 25555585 DOI: 10.1007/978-1-4939-2253-6_14 |
0.324 |
|
| 2015 |
Tholey RM, Lal S, Jimbo M, Burkhart RA, Blanco FF, Cozzitorto JA, Eisenberg JD, Jiang W, Iacobuzio-Donahue CA, Witkiewicz AK, Glbert M, Yeo CJ, Brody JR, Sawicki JA, Winter JM. MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. Molecular Cancer Research : McR. 13: 439-48. PMID 25336517 DOI: 10.1158/1541-7786.Mcr-14-0199 |
0.439 |
|
| 2015 |
Pishvaian MJ, Wang H, He AR, Ley L, Dorsch-Vogel K, Hartley ML, Carney E, Weiner LM, Smaglo BG, Brody JR, Marshall J. A pilot study of molecularly tailored therapy for patients with metastatic pancreatic cancer (MPC). Journal of Clinical Oncology. 33: 329-329. DOI: 10.1200/Jco.2015.33.3_Suppl.329 |
0.315 |
|
| 2015 |
Blanco FF, Meisner-Kober NC, Londin E, Rigoutsos I, Risbud MV, Yeo CJ, Winter JM, Brody JR. Abstract A05: The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through post-transcriptional regulation of the serine-threonine kinase PIM1 Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-A05 |
0.456 |
|
| 2015 |
Blanco FF, Meisner-Kober N, Londin E, Rigoutsos I, Winter J, Yeo C, Brody J. Abstract A71: Post-transcriptional regulation of the proto-oncogene PIM1 by the mRNA stability factor HuR: implications for pancreatic cancer therapeutic response and cell survival Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-A71 |
0.49 |
|
| 2015 |
Londin ER, Loher P, Quann K, Delgrosso K, Fortina P, Brody J, Rigoutsos I. Abstract A34: Regulation of pancreatic cells by isomiRs Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-A34 |
0.392 |
|
| 2015 |
Chand SN, Kamath AR, Meisner-Kober N, Yeo CJ, Winter JM, Brody JR. Abstract 5476: A novel PARP inhibitor resistance mechanism mediated by the RNA-binding protein HuR Cancer Research. 75: 5476-5476. DOI: 10.1158/1538-7445.Am2015-5476 |
0.451 |
|
| 2015 |
Jimbo M, Blanco FF, Screnci B, Cosma G, Alexeev V, Huang Y, Winter JM, Yeo CJ, Sawicki JA, Brody JR. Abstract 5133: The RNA-binding protein HuR facilitates proliferation and metastasis in human pancreatic ductal adenocarcinoma Cancer Research. 75: 5133-5133. DOI: 10.1158/1538-7445.Am2015-5133 |
0.451 |
|
| 2015 |
Sawicki JA, Huang Y, Brody JR, Getts RC, Rhodes K, Gerhart J. Abstract 3542: Inhibition of HuR effectively suppresses ovarian tumor growth in mice Cancer Research. 75: 3542-3542. DOI: 10.1158/1538-7445.Am2015-3542 |
0.431 |
|
| 2015 |
Blanco FF, Jimbo M, Enyenihi L, Meisner-Kober N, Londin E, Rigoutsos I, Risbud M, McCue P, Yeo C, Winter J, Brody JR. Abstract 2113: Targeting tumor-associated hypoxia to overcome chemoresistance in pancreatic ductal adenocarcinoma (PDA) Cancer Research. 75: 2113-2113. DOI: 10.1158/1538-7445.Am2015-2113 |
0.342 |
|
| 2015 |
Lal S, Chand SN, Dylgjeri E, Yeo CJ, Winter JM, Brody JR. Abstract 1656: MK-1775 (WEE1 inhibition) lacks efficacy against DNA repair deficient pancreatic cancer cells Cancer Research. 75: 1656-1656. DOI: 10.1158/1538-7445.Am2015-1656 |
0.409 |
|
| 2015 |
Blanco FF, Zarei M, Brody JR, Boros LG, Winter JM. Abstract 1191: The RNA binding protein, HuR, regulates pancreatic cancer cell metabolism Cancer Research. 75: 1191-1191. DOI: 10.1158/1538-7445.Am2015-1191 |
0.349 |
|
| 2014 |
Blanco FF, Pishvaian MJ, Brody JR. Upgrading gemcitabine with recycled kinase inhibitors. Cell Cycle (Georgetown, Tex.). 13: 2810-1. PMID 25486467 DOI: 10.4161/15384101.2014.954211 |
0.387 |
|
| 2014 |
Jimbo M, Knudsen KE, Brody JR. Fusing transcriptomics to progressive prostate cancer. The American Journal of Pathology. 184: 2608-10. PMID 25128905 DOI: 10.1016/J.Ajpath.2014.08.001 |
0.359 |
|
| 2014 |
McAllister F, Pineda DM, Jimbo M, Lal S, Burkhart RA, Moughan J, Winter KA, Abdelmohsen K, Gorospe M, De Jesus Acosta A, Lankapalli RH, Winter JM, Yeo CJ, Witkiewicz AK, Iacobuzio-Donahue CA, ... ... Brody JR, et al. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: A dual-institutional follow-up with the RTOG 9704 trial Cancer Biology and Therapy. 15: 688-698. PMID 24618665 DOI: 10.4161/Cbt.28413 |
0.394 |
|
| 2014 |
Lal S, Burkhart RA, Beeharry N, Bhattacharjee V, Londin ER, Cozzitorto JA, Romeo C, Jimbo M, Norris ZA, Yeo CJ, Sawicki JA, Winter JM, Rigoutsos I, Yen TJ, Brody JR. HuR posttranscriptionally regulates WEE1: Implications for the DNA damage response in pancreatic cancer cells Cancer Research. 74: 1128-1140. PMID 24536047 DOI: 10.1158/0008-5472.Can-13-1915 |
0.415 |
|
| 2014 |
Steffen JD, Tholey RM, Langelier MF, Planck JL, Schiewer MJ, Lal S, Bildzukewicz NA, Yeo CJ, Knudsen KE, Brody JR, Pascal JM. Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer. Cancer Research. 74: 31-7. PMID 24189460 DOI: 10.1158/0008-5472.Can-13-1701 |
0.388 |
|
| 2014 |
Schiewer MJ, Steffen J, Tholey R, Brody JR, Pascal J, Lin J, Den R, Feng FY, Gomella LG, Dicker A, Kelly WK, Knudsen KE. Leveraging the DNA damage and transcriptional-regulatory roles of PARP-1 as a means to improve prostate cancer therapy. Journal of Clinical Oncology. 32: 179-179. DOI: 10.1200/Jco.2014.32.4_Suppl.179 |
0.415 |
|
| 2013 |
Steffen JD, Brody JR, Armen RS, Pascal JM. Structural Implications for Selective Targeting of PARPs. Frontiers in Oncology. 3: 301. PMID 24392349 DOI: 10.3389/Fonc.2013.00301 |
0.357 |
|
| 2013 |
Burkhart RA, Pineda DM, Chand SN, Romeo C, Londin ER, Karoly ED, Cozzitorto JA, Rigoutsos I, Yeo CJ, Brody JR, Winter JM. HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer Rna Biology. 10: 1312-1323. PMID 23807417 DOI: 10.4161/Rna.25274 |
0.447 |
|
| 2013 |
Comstock CE, Augello MA, Goodwin JF, de Leeuw R, Schiewer MJ, Ostrander WF, Burkhart RA, McClendon AK, McCue PA, Trabulsi EJ, Lallas CD, Gomella LG, Centenera MM, Brody JR, Butler LM, et al. Targeting cell cycle and hormone receptor pathways in cancer. Oncogene. 32: 5481-91. PMID 23708653 DOI: 10.1038/Onc.2013.83 |
0.352 |
|
| 2013 |
Burkhart RA, Peng Y, Norris ZA, Tholey RM, Talbott VA, Liang Q, Ai Y, Miller K, Lal S, Cozzitorto JA, Witkiewicz AK, Yeo CJ, Gehrmann M, Napper A, Winter JM, ... ... Brody JR, et al. Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival Molecular Cancer Research. 11: 901-911. PMID 23696131 DOI: 10.1158/1541-7786.Mcr-12-0699 |
0.411 |
|
| 2013 |
Lin WC, Rajbhandari N, Liu C, Sakamoto K, Zhang Q, Triplett AA, Batra SK, Opavsky R, Felsher DW, DiMaio DJ, Hollingsworth MA, Morris JP, Hebrok M, Witkiewicz AK, Brody JR, et al. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Research. 73: 1821-30. PMID 23467612 DOI: 10.1158/0008-5472.Can-12-2067 |
0.48 |
|
| 2013 |
Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer Journal of Surgical Oncology. 107: 15-22. PMID 22729569 DOI: 10.1002/Jso.23192 |
0.348 |
|
| 2013 |
Pishvaian MJ, Wang H, Zhuang T, He AR, Hwang JJ, Hankin A, Ley L, White K, Littman SJ, Weiner LM, Marshall J, Brody JR. A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC). Journal of Clinical Oncology. 31: 147-147. DOI: 10.1200/Jco.2013.31.4_Suppl.147 |
0.303 |
|
| 2013 |
Lal S, Burkhart RA, Norris Z, Beeharry N, Bhattacharjee V, Rigoutsos I, Yen T, Yeo CJ, Winter JM, Brody JR. Abstract 628: A novel chemoresistance mechanism: HuR post-trancriptionally regulates WEE1, the mitotic inhibitor, upon DNA damage in pancreatic adenocarcinoma cells. Cancer Research. 73: 628-628. DOI: 10.1158/1538-7445.Am2013-628 |
0.398 |
|
| 2013 |
Winter JM, Burkhart RA, Pineda DM, Chand S, Cozzitorto J, Yeo CJ, Brody JR. Abstract 5394: HuR affects pancreatic cancer metabolism through post-transcriptional control of core metabolic enzymes. Cancer Research. 73: 5394-5394. DOI: 10.1158/1538-7445.Am2013-5394 |
0.418 |
|
| 2012 |
Valsecchi ME, Littman SJ, Holdbrook T, Leiby B, Mitchell EP, Yeo C, Brody JR, Witkiewicz A. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 246. PMID 27982944 DOI: 10.1200/jco.2012.30.4_suppl.246 |
0.335 |
|
| 2012 |
Tholey R, Sawicki JA, Brody JR. Molecular-based and alternative therapies for pancreatic cancer: looking "out of the box". Cancer Journal (Sudbury, Mass.). 18: 665-73. PMID 23187855 DOI: 10.1097/Ppo.0B013E3182793Ff6 |
0.47 |
|
| 2012 |
Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, Liu F, Planck JL, Ravindranathan P, Chinnaiyan AM, McCue P, Gomella LG, Raj GV, Dicker AP, Brody JR, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discovery. 2: 1134-49. PMID 22993403 DOI: 10.1158/2159-8290.Cd-12-0120 |
0.438 |
|
| 2012 |
Winter JM, Tang LH, Klimstra DS, Brennan MF, Brody JR, Rocha FG, Jia X, Qin LX, D'Angelica MI, DeMatteo RP, Fong Y, Jarnagin WR, O'Reilly EM, Allen PJ. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. Plos One. 7: e40157. PMID 22792233 DOI: 10.1371/Journal.Pone.0040157 |
0.349 |
|
| 2012 |
Pineda DM, Rittenhouse DW, Valley CC, Cozzitorto JA, Burkhart RA, Leiby B, Winter JM, Weber MC, Londin ER, Rigoutsos I, Yeo CJ, Gorospe M, Witkiewicz AK, Sachs JN, Brody JR. HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells. Cancer Biology & Therapy. 13: 946-55. PMID 22785201 DOI: 10.4161/Cbt.20952 |
0.43 |
|
| 2012 |
Valsecchi ME, Holdbrook T, Leiby BE, Pequignot E, Littman SJ, Yeo CJ, Brody JR, Witkiewicz AK. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? Bmc Cancer. 12: 104. PMID 22436573 DOI: 10.1200/Jco.2012.30.4_Suppl.246 |
0.441 |
|
| 2012 |
Talbott VA, Yeo CJ, Brody JR, Witkiewicz AK. Molecular profiling of synchronous and metachronous cancers of the pancreas reveal molecular mimicry between samples from the same patient. The Journal of Surgical Research. 176: 154-8. PMID 22118834 DOI: 10.1016/J.Jss.2011.09.043 |
0.374 |
|
| 2012 |
Winter JM, Burkhart RA, Cozzitorto J, Yeo CJ, Brody JR. Abstract A99: Posttranscriptional gene regulation by HuR can explain metabolic reprogramming in acutely stressed pancreatic cancer cells. Cancer Research. 72. DOI: 10.1158/1538-7445.Panca2012-A99 |
0.397 |
|
| 2012 |
Lal S, Bhattacharjee V, Yen T, Burkhart RA, Pineda DM, Yeo CJ, Winter JM, Rigoutsos I, Brody JR. Abstract A18: HuR, an RNA binding protein, is critical for the DNA damage response in pancreatic cancer cells. Cancer Research. 72. DOI: 10.1158/1538-7445.Panca2012-A18 |
0.415 |
|
| 2012 |
Sawicki JA, Huang Y, Yeo CJ, Gogoi RP, Love K, Anderson DG, Witkiewicz AK, Brody JR. Abstract 5630: Nanotherapeutic silencing of HuR: Targeting a tumor-promoting response in ovarian cancer Cancer Research. 72: 5630-5630. DOI: 10.1158/1538-7445.Am2012-5630 |
0.472 |
|
| 2012 |
Burkhart R, Pineda D, Cozzitorto J, Yeo C, Brody J, Winter J. Abstract 5144: RNA-binding protein HuR supports post-transcriptional regulation of pancreatic cancer cell metabolism Cancer Research. 72: 5144-5144. DOI: 10.1158/1538-7445.Am2012-5144 |
0.429 |
|
| 2012 |
Burkhart R, Brody J, Yeo C, Winter J. Behind the Warburg Effect: Rna-Binding Protein, HuR, Can Regulate Pancreatic Cancer Cell Metabolism Journal of Surgical Research. 172: 341. DOI: 10.1016/J.Jss.2011.11.718 |
0.379 |
|
| 2012 |
Pineda D, Norris Z, Winter J, Dixon D, Witkiewicz A, Yeo C, Brody J. Tristetraprolin (TTP) Has Tumor Suppressor Characteristics in Pancreatic Cancer Cells and Can Regulate Gemcitabine Efficacy Journal of Surgical Research. 172: 341. DOI: 10.1016/J.Jss.2011.11.712 |
0.352 |
|
| 2012 |
McIntyre C, Talbott V, Winter J, Gonye G, Simone N, Witkiewicz A, Yeo C, Brody J. A Supervised Survey of MicroRNAs As Candidate Regulators of the Tumor Promoting RNA Binding Protein, HuR, in Pancreatic Cancer Cells Journal of Surgical Research. 172: 341. DOI: 10.1016/j.jss.2011.11.705 |
0.304 |
|
| 2012 |
Brody JR, Rittenhouse DW, Witkiewicz AK, Yeo CJ. Pancreatic cancer and premalignant tumors: Molecular aspects Blumgart's Surgery of the Liver, Biliary Tract, and Pancreas. 1: 123-134. DOI: 10.1016/B978-1-4377-1454-8.00008-4 |
0.31 |
|
| 2011 |
Pishvaian MJ, Slack R, Witkiewicz A, He AR, Hwang JJ, Hankin A, Ley L, Apte SK, Littman SJ, Weiner LM, Marshall J, Brody JR. A phase I/II study of the PARP inhibitor, ABT-888 plus 5-fluorouracil and oxaliplatin (modified FOLFOX-6) in patients with metastatic pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS170. PMID 28023043 DOI: 10.1200/Jco.2011.29.15_Suppl.Tps170 |
0.408 |
|
| 2011 |
Pishvaian MJ, Slack R, Witkiewicz A, He AR, Hwang JJ, Hankin A, Dorsch-Vogel K, Kuda D, McAndrew T, Weiner LM, Marshall J, Brody JR. A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3502. PMID 28020342 DOI: 10.1200/Jco.2011.29.15_Suppl.3502 |
0.38 |
|
| 2011 |
Wu KN, Queenan M, Brody JR, Potoczek M, Sotgia F, Lisanti MP, Witkiewicz AK. Loss of stromal caveolin-1 expression in malignant melanoma metastases predicts poor survival. Cell Cycle (Georgetown, Tex.). 10: 4250-5. PMID 22134245 DOI: 10.4161/Cc.10.24.18551 |
0.363 |
|
| 2011 |
Brody JR, Gonye GE. HuR's role in gemcitabine efficacy: an exception or opportunity? Wiley Interdisciplinary Reviews. Rna. 2: 435-44. PMID 21957028 DOI: 10.1002/Wrna.62 |
0.451 |
|
| 2011 |
Brody JR, Witkiewicz AK, Yeo CJ. The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer. Advances in Surgery. 45: 301-21. PMID 21954696 DOI: 10.1016/J.Yasu.2011.04.002 |
0.356 |
|
| 2011 |
Witkiewicz AK, Kline J, Queenan M, Brody JR, Tsirigos A, Bilal E, Pavlides S, Ertel A, Sotgia F, Lisanti MP. Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle (Georgetown, Tex.). 10: 1794-809. PMID 21521946 DOI: 10.4161/Cc.10.11.15675 |
0.456 |
|
| 2011 |
Brody JR, Witkiewicz AK, Liu F, Yeo CJ, Qio S, Sawicki JA. Abstract LB-231: Therapeutic targeting of multiple pancreatic tumor promoting-pathways in vivo: nanotherapeutic silencing of HuR Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-231 |
0.482 |
|
| 2011 |
Rittenhouse DW, Valley C, Cozzitorto JA, Richards NG, Talbott VA, Yeo CJ, Sachs JN, Witkiewicz AK, Brody JR. Abstract 4100: HuR regulates death receptor-5 (DR5, TRAIL-R2)-targeted treatment of pancreatic cancer cells Cancer Research. 71: 4100-4100. DOI: 10.1158/1538-7445.Am2011-4100 |
0.451 |
|
| 2011 |
Witkiewicz AK, Kline J, Queenan M, Brody J, Sotgia F, Tsirigos A, Lisanti MP. Abstract 1510: Transcriptional profiling of a lethal breast cancer tumor microenvironment Cancer Research. 71: 1510-1510. DOI: 10.1158/1538-7445.Am2011-1510 |
0.467 |
|
| 2011 |
Talbott VA, Ahn K, Rittenhouse DW, Richards NG, Witkiewicz A, Kennedy EP, Gorospe M, Yeo CJ, Brody JR. A Promising Novel Target in Pancreatic Cancer: HuR Modulates Multiple Core Signaling Pathways Required for Pancreatic Tumorigenesis Gastroenterology. 140: S-1026. DOI: 10.1016/S0016-5085(11)64265-0 |
0.378 |
|
| 2011 |
Kennedy EP, Brody JR, Witkiewicz A, Lavu H, Sauter PK, Grenda D, MacRae D, Williams F, Rosato EL, Yeo CJ. Clinical Practice as an Engine Driving a Translational Research Program in Pancreatic Cancer Gastroenterology. 140: S-1021. DOI: 10.1016/S0016-5085(11)64242-X |
0.313 |
|
| 2010 |
Williams TK, Costantino CL, Bildzukewicz NA, Richards NG, Rittenhouse DW, Einstein L, Cozzitorto JA, Keen JC, Dasgupta A, Gorospe M, Gonye GE, Yeo CJ, Witkiewicz AK, Brody JR. pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs. Plos One. 5: e15455. PMID 21152064 DOI: 10.1371/Journal.Pone.0015455 |
0.506 |
|
| 2010 |
Huang YH, Cozzitorto JA, Richards NG, Eltoukhy AA, Yeo CJ, Langer R, Anderson DG, Brody JR, Sawicki JA. CanScript, an 18-Base pair DNA sequence, boosts tumor cell-specific promoter activity: implications for targeted gene therapy. Cancer Biology & Therapy. 10: 878-84. PMID 20798601 DOI: 10.4161/Cbt.10.9.13234 |
0.416 |
|
| 2010 |
Brody JR, Witkiewicz AK. CXCR4 signaling identifies a role for IFT2 in ER-negative breast cancers. Cancer Biology & Therapy. 10: 615-6. PMID 20686361 DOI: 10.4161/Cbt.10.6.12906 |
0.318 |
|
| 2010 |
Toll AD, Dasgupta A, Potoczek M, Yeo CJ, Kleer CG, Brody JR, Witkiewicz AK. Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Human Pathology. 41: 1205-9. PMID 20573371 DOI: 10.1016/J.Humpath.2010.03.004 |
0.414 |
|
| 2010 |
Witkiewicz AK, Dasgupta A, Sammons S, Er O, Potoczek MB, Guiles F, Sotgia F, Brody JR, Mitchell EP, Lisanti MP. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biology & Therapy. 10: 135-43. PMID 20431349 DOI: 10.4161/Cbt.10.2.11983 |
0.367 |
|
| 2010 |
Showalter SL, Charles S, Belin J, Cozzitorto J, Einstein P, Richards NG, Sauter PK, Kennedy EP, Witkiewicz A, Brody JR, Yeo CJ. Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future. Expert Opinion On Drug Delivery. 7: 273-84. PMID 20201734 DOI: 10.1517/17425240903544462 |
0.372 |
|
| 2010 |
Showalter SL, Wang Z, Costantino CL, Witkiewicz AK, Yeo CJ, Brody JR, Carr BI. Naturally occurring K vitamins inhibit pancreatic cancer cell survival through a caspase-dependent pathway. Journal of Gastroenterology and Hepatology. 25: 738-44. PMID 19929921 DOI: 10.1111/J.1440-1746.2009.06085.X |
0.409 |
|
| 2010 |
Costantino CL, Richards NG, Cozzitorto J, Rittenhouse D, Gonye G, Yeo CJ, Witkiewicz A, Brody JR. Abstract 3643: Manipulation of HuR expression alters the efficacy of PARP-inhibitors in pancreatic and ovarian cancer cells Cancer Research. 70: 3643-3643. DOI: 10.1158/1538-7445.Am10-3643 |
0.496 |
|
| 2010 |
Sawicki JA, Huang Y, Cozzitorto J, Langer R, Anderson DG, Brody JR. Abstract 2: Naked CanScript, an 18-base pair sequence, has tumor cell-specific promoter activity in vivo: Implications for targeted gene therapy Cancer Research. 70: 2-2. DOI: 10.1158/1538-7445.Am10-2 |
0.475 |
|
| 2009 |
Brody J, Dasgupta A, Costantino CL, Kennedy E, Yeo CJ, Witkiewicz AK. Correlation of HuR cytoplasmic expression in pancreatic cancer and overall patient survival when treated with gemcitabine in the adjuvant setting. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 11097. PMID 27963125 DOI: 10.1200/Jco.2009.27.15_Suppl.11097 |
0.442 |
|
| 2009 |
Cotton RT, Li D, Scherer SE, Muzny DM, Hodges SE, Catania RL, Witkiewicz AK, Brody JR, Kennedy EP, Yeo CJ, Brunicardi FC, Gibbs RA, Gingras MC, Fisher WE. Single nucleotide polymorphism in RECQL and survival in resectable pancreatic adenocarcinoma. Hpb : the Official Journal of the International Hepato Pancreato Biliary Association. 11: 435-44. PMID 19768149 DOI: 10.1111/J.1477-2574.2009.00089.X |
0.314 |
|
| 2009 |
Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M, Brody JR. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Research. 69: 4567-72. PMID 19487279 DOI: 10.1158/0008-5472.Can-09-0371 |
0.479 |
|
| 2009 |
Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, Brody JR. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. Journal of the American College of Surgeons. 208: 781-7; discussion 78. PMID 19476837 DOI: 10.1016/J.Jamcollsurg.2008.12.018 |
0.439 |
|
| 2009 |
Yeo TP, Hruban RH, Brody J, Brune K, Fitzgerald S, Yeo CJ. Assessment of "gene-environment" interaction in cases of familial and sporadic pancreatic cancer. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. 13: 1487-94. PMID 19459017 DOI: 10.1007/S11605-009-0923-6 |
0.377 |
|
| 2009 |
Brody JR, Costantino CL, Berger AC, Sato T, Lisanti MP, Yeo CJ, Emmons RV, Witkiewicz AK. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle (Georgetown, Tex.). 8: 1930-4. PMID 19448397 DOI: 10.4161/Cc.8.12.8745 |
0.342 |
|
| 2009 |
Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR, Lisanti MP. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. The American Journal of Pathology. 174: 2023-34. PMID 19411448 DOI: 10.2353/Ajpath.2009.080873 |
0.39 |
|
| 2009 |
Brody JR, Costantino CL, Potoczek M, Cozzitorto J, McCue P, Yeo CJ, Hruban RH, Witkiewicz AK. Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 22: 651-9. PMID 19270646 DOI: 10.1038/Modpathol.2009.15 |
0.332 |
|
| 2009 |
Brody JR, Hucl T, Costantino CL, Eshleman JR, Gallmeier E, Zhu H, van der Heijden MS, Winter JM, Wikiewicz AK, Yeo CJ, Kern SE. Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence. Cancer Research. 69: 984-91. PMID 19155291 DOI: 10.1158/0008-5472.Can-08-3610 |
0.455 |
|
| 2009 |
Showalter SL, Wang Z, Costantino CL, Witkiewicz A, Yeo CJ, Brody JR, Carr BI. M1758 Naturally Occurring K Vitamins Inhibit Pancreatic Cancer Cell Line Growth Gastroenterology. 136: A-906. DOI: 10.1016/S0016-5085(09)64186-X |
0.357 |
|
| 2009 |
Bildzukewicz NA, Costantino CL, Cozzitorto JA, Pascal JM, Witkiewicz A, Kennedy EP, Yeo CJ, Brody JR. An evaluation of a new chemotherapeutic strategy: Exogenous mutant PARP-1 expression sensitizes pancreatic cancer cells to clinically available platinum-based agents Journal of the American College of Surgeons. 209: S53. DOI: 10.1016/J.Jamcollsurg.2009.06.124 |
0.419 |
|
| 2008 |
Showalter SL, Huang YH, Witkiewicz A, Costantino CL, Yeo CJ, Green JJ, Langer R, Anderson DG, Sawicki JA, Brody JR. Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells. Cancer Biology & Therapy. 7: 1584-90. PMID 19039293 DOI: 10.4161/Cbt.7.10.6562 |
0.506 |
|
| 2008 |
Witkiewicz AK, Nguyen KH, Dasgupta A, Kennedy EP, Yeo CJ, Lisanti MP, Brody JR. Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: implications for tumor progression and clinical outcome. Cell Cycle (Georgetown, Tex.). 7: 3021-5. PMID 18802406 DOI: 10.4161/Cc.7.19.6719 |
0.47 |
|
| 2008 |
Hostetter C, Licata LA, Witkiewicz A, Costantino CL, Yeo CJ, Brody JR, Keen JC. Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biology & Therapy. 7: 1496-506. PMID 18769129 DOI: 10.4161/Cbt.7.9.6490 |
0.373 |
|
| 2008 |
Williams TK, Yeo CJ, Brody J. Does this band make sense? Limits to expression based cancer studies Cancer Letters. 271: 81-84. PMID 18602748 DOI: 10.1016/J.Canlet.2008.05.033 |
0.381 |
|
| 2008 |
Hucl T, Rago C, Gallmeier E, Brody JR, Gorospe M, Kern SE. A syngeneic variance library for functional annotation of human variation: application to BRCA2. Cancer Research. 68: 5023-30. PMID 18593900 DOI: 10.1158/0008-5472.Can-07-6189 |
0.362 |
|
| 2008 |
Witkiewicz A, Williams TK, Cozzitorto J, Durkan B, Showalter SL, Yeo CJ, Brody JR. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. Journal of the American College of Surgeons. 206: 849-54; discussion 8. PMID 18471709 DOI: 10.1016/J.Jamcollsurg.2007.12.014 |
0.301 |
|
| 2008 |
Showalter SL, Showalter TN, Witkiewicz A, Havens R, Kennedy EP, Hucl T, Kern SE, Yeo CJ, Brody JR. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer Biology & Therapy. 7: 986-94. PMID 18443433 DOI: 10.4161/Cbt.7.7.6181 |
0.36 |
|
| 2008 |
Showalter SL, Witkiewicz A, Cozzitorto JA, Sauter PK, Kennedy EP, Yeo CJ, Brody JR. W1841 A Model for Defining Molecular Aspects of Pancreatic Ductal Adenocarcinoma Patients for Targeted Adjuvant Therapy Gastroenterology. 134: A-913. DOI: 10.1016/S0016-5085(08)64289-4 |
0.304 |
|
| 2008 |
Brody JR, Williams TK, Witkiewicz A, Cozzitorto J, Pasternack G, Kadkol S, Yeo CJ. M1858 pp32 Is a Key Regulator of Cellular Differentiation: Implications for Anti-Cancer Therapy Gastroenterology. 134: A-877. DOI: 10.1016/S0016-5085(08)64112-8 |
0.703 |
|
| 2007 |
Hucl T, Brody JR, Gallmeier E, Iacobuzio-Donahue CA, Farrance IK, Kern SE. High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif. Cancer Research. 67: 9055-65. PMID 17909009 DOI: 10.1158/0008-5472.Can-07-0474 |
0.463 |
|
| 2007 |
Brody JR, Witkiewicz A, Williams TK, Kadkol SS, Cozzitorto J, Durkan B, Pasternack GR, Yeo CJ. Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 20: 1238-44. PMID 17906614 DOI: 10.1038/Modpathol.3800974 |
0.747 |
|
| 2007 |
Gallmeier E, Hucl T, Calhoun ES, Cunningham SC, Bunz F, Brody JR, Kern SE. Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer. Cancer Biology & Therapy. 6: 654-60. PMID 17387268 DOI: 10.4161/Cbt.6.5.3978 |
0.403 |
|
| 2007 |
Gallmeier E, Hucl T, Brody JR, Dezentje DA, Tahir K, Kasparkova J, Brabec V, Bachman KE, Kern SE. High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells. Cancer Research. 67: 2169-77. PMID 17332347 DOI: 10.1158/0008-5472.Can-06-2711 |
0.401 |
|
| 2006 |
Brody JR, Hucl T, Gallmeier E, Winter JM, Kern SE, Murphy KM. Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy. Cancer Research. 66: 9369-73. PMID 17018589 DOI: 10.1158/0008-5472.Can-06-2165 |
0.398 |
|
| 2006 |
Brody JR, Gallmeier E, Yoshimura K, Hucl T, Kulesza P, Canto MI, Hruban RH, Schulick RD, Kern SE. A proposed clinical test for monitoring fluoropyrimidine therapy: detection and stability of thymidylate synthase ternary complexes. Cancer Biology & Therapy. 5: 923-7. PMID 16855390 DOI: 10.4161/Cbt.5.8.2976 |
0.34 |
|
| 2006 |
Gallmeier E, Calhoun ES, Rago C, Brody JR, Cunningham SC, Hucl T, Gorospe M, Kohli M, Lengauer C, Kern SE. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gastroenterology. 130: 2145-54. PMID 16762635 DOI: 10.1053/J.Gastro.2006.03.016 |
0.429 |
|
| 2006 |
Winter JM, Brody JR, Kern SE. Multiple-criterion evaluation of reported mutations: A proposed scoring system for the intragenic somatic mutation literature Cancer Biology and Therapy. 5: 360-370. PMID 16575211 DOI: 10.4161/Cbt.5.4.2552 |
0.308 |
|
| 2006 |
van der Heijden MS, Brody JR, Elghalbzouri-Maghrani E, Zdzienicka MZ, Kern SE. Does tumorigenesis select for or against mutations of the DNA repair-associated genes BRCA2 and MRE11?: considerations from somatic mutations in microsatellite unstable (MSI) gastrointestinal cancers. Bmc Genetics. 7: 3. PMID 16417627 DOI: 10.1186/1471-2156-7-3 |
0.352 |
|
| 2005 |
van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, DeMarzo AM, Offerhaus GJ, Isacoff WH, Hruban RH, Kern SE. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 7508-15. PMID 16243825 DOI: 10.1158/1078-0432.Ccr-05-1048 |
0.43 |
|
| 2004 |
van der Heijden MS, Brody JR, Gallmeier E, Cunningham SC, Dezentje DA, Shen D, Hruban RH, Kern SE. Functional defects in the fanconi anemia pathway in pancreatic cancer cells. The American Journal of Pathology. 165: 651-7. PMID 15277238 DOI: 10.1016/S0002-9440(10)63329-9 |
0.452 |
|
| 2004 |
Kochevar GJ, Brody JR, Kadkol SS, Murphy KM, Pasternack GR. Identification of a functional mutation in pp32r1 (ANP32C). Human Mutation. 23: 546-51. PMID 15146458 DOI: 10.1002/Humu.20030 |
0.709 |
|
| 2004 |
Van Der Heijden MS, Brody JR, Kern SE. Functional screen of the fanconi anemia pathway in cancer cells by Fancd2 immunoblot. Cancer Biology & Therapy. 3: 534-7. PMID 15107617 DOI: 10.4161/Cbt.3.6.844 |
0.438 |
|
| 2004 |
Brody JR, Kadkol SS, Hauer MC, Rajaii F, Lee J, Pasternack GR. pp32 reduction induces differentiation of TSU-Pr1 cells. The American Journal of Pathology. 164: 273-83. PMID 14695340 DOI: 10.1016/S0002-9440(10)63117-3 |
0.714 |
|
| 2001 |
Kadkol SS, El Naga GA, Brody JR, Bai J, Gusev Y, Dooley WC, Pasternack GR. Expression of pp32 gene family members in breast cancer. Breast Cancer Research and Treatment. 68: 65-73. PMID 11678310 DOI: 10.1023/A:1017919507109 |
0.683 |
|
| 2001 |
Bai J, Brody JR, Kadkol SS, Pasternack GR. Tumor suppression and potentiation by manipulation of pp32 expression. Oncogene. 20: 2153-60. PMID 11360199 DOI: 10.1038/Sj.Onc.1204294 |
0.713 |
|
| 1999 |
Kadkol SS, Brody JR, Pevsner J, Bai J, Pasternack GR. Correction to "Modulation of oncogenic potential by alternative gene use in human prostate cancer" Nature Medicine. 5: 1087. PMID 10471270 DOI: 10.1038/12530 |
0.679 |
|
| 1999 |
Brody JR, Kadkol SS, Mahmoud MA, Rebel JM, Pasternack GR. Identification of sequences required for inhibition of oncogene-mediated transformation by pp32. The Journal of Biological Chemistry. 274: 20053-5. PMID 10400610 DOI: 10.1074/Jbc.274.29.20053 |
0.692 |
|
| 1999 |
Kadkol SS, Brody JR, Pevsner J, Bai J, Pasternack GR. Modulation of oncogenic potential by alternative gene use in human prostate cancer. Nature Medicine. 5: 275-9. PMID 10086381 DOI: 10.1038/6488 |
0.7 |
|
| 1998 |
Kadkol SS, Brody JR, Epstein JI, Kuhajda FP, Pasternack GR. Novel nuclear phosphoprotein pp32 is highly expressed in intermediate- and high-grade prostate cancer. The Prostate. 34: 231-7. PMID 9492852 DOI: 10.1002/(Sici)1097-0045(19980215)34:3<231::Aid-Pros11>3.0.Co;2-F |
0.74 |
|
| 1996 |
Chen TH, Brody JR, Romantsev FE, Yu JG, Kayler AE, Voneiff E, Kuhajda FP, Pasternack GR. Structure of pp32, an acidic nuclear protein which inhibits oncogene-induced formation of transformed foci. Molecular Biology of the Cell. 7: 2045-56. PMID 8970164 DOI: 10.1091/Mbc.7.12.2045 |
0.689 |
|
| Show low-probability matches. |